

Application No.: 10/688,059
 Reply to Office action of July 17, 2006

RECEIVED
 CENTRAL FAX CENTER
 OCT 13 2006

Remarks/Arguments

Claim 1 has been amended to limit the claims to recite a particular polymer, support for which is found at page 12 of the specification. Claim 14 has also been added and corresponds to Claim 1 but limits the active agent to exendin-4, support for which is found at page 9 of the specification. Dependent Claims 2 – 13 and 15 - 19 have been added. Support for each claim is found in the following table:

Claim	Exemplary Specification Support
2	Page 8, lines 21-23
3	Page 9, lines 20-27
4	Page 9, lines 20-27
5	Page 9, lines 20-27
6	Page 9, lines 20-27
7	Page 8, lines 6-9
8	Page 8, lines 6-9
9	Page 8, lines 6-9
10	Page 8, lines 1-5
11	Page 8, lines 1-5
12	Page 8, lines 1-5
13	Page 8, lines 1-5
15	Page 12, lines 8-27
16	Page 8, lines 6-9
17	Page 9, lines 20-27
18	Page 20, line 15 et seq.
19	Page 20, line 15 et seq.

Claim 1 has been rejected as being anticipated by Yim et al. Yim et al. describes a formulation for bone morphogenic proteins containing sucrose, glycine, glutamate and, preferably, a surfactant such as polysorbate, for example, in a polymer matrix. The claims, as amended, no

Application No.: 10/688,059
Reply to Office action of July 17, 2006

longer embrace the addition of excipients such as glutamate and polysorbate. Further, Claims 2-5, 14-17 and 19 are directed to the incorporation of proteins distinct from BMPs. It is believed that the rejection is rendered moot by the amendments. Withdrawal is respectfully requested.

If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 251-3509.

Respectfully submitted,

ELMORE PATENT LAW GROUP, P.C.


By _____
Carolyn S. Elmore
Registration No. 37,567
Telephone: (978) 251-3509
Facsimile: (978) 251-3973

N. Chelmsford, MA 01863

Dated: 10/13/06

Page 6 of 6